Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and ...
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to ...
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...